Licitra Lisa Francesca Linda

Associate Professor
Competition sector


University email address



  • Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma / R. Mesia, P. Bossi, A.R. Hansen, C.Y. Hsieh, L.F. Licitra, E.H. Tan, P. Chen, J. Miller, L.L. Siu, R.I. Haddad. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 123(2019 Dec), pp. 138-145.
  • PD-1 immunotherapy for recurrent or metastatic HNSCC / R.L. Ferris, L. Licitra. - In: THE LANCET. - ISSN 0140-6736. - 394:10212(2019 Nov 23), pp. 1882-1884.
  • Could the extreme conformality achieved with proton therapy in paranasal sinuses cancers accidentally results in a high rate of leptomeningeal progression? / E. Orlandi, N.A. Iacovelli, A. Cavallo, C. Resteghini, L. Gandola, L. Licitra, P. Bossi. - In: HEAD & NECK. - ISSN 1043-3074. - 41:10(2019 Oct), pp. 3733-3735.
  • Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract / L.D. Locati, S. Cavalieri, C. Bergamini, C. Resteghini, S. Alfieri, G. Calareso, P. Bossi, F. Perrone, E. Tamborini, P. Quattrone, R. Granata, D. Galbiati, F. Platini, E. Orlandi, L. Mariani, L. Licitra. - In: HEAD & NECK. - ISSN 1043-3074. - 41:10(2019 Oct), pp. 3670-3676.
  • Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck : subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial / R. Haddad, J. Guigay, U. Keilholz, P.M. Clement, J. Fayette, L. de Souza Viana, F. Rolland, D. Cupissol, L. Geoffrois, G. Kornek, L. Licitra, B. Melichar, U. Ribaldo Nicolau, D. Rauch, S. Zanetta-Devauges, E.E.W. Cohen, J.P. Machiels, M. Tahara, J. Vermorken, Y. Geng, E. Zografos, T. Gauler. - In: ORAL ONCOLOGY. - ISSN 1368-8375. - 97(2019 Oct), pp. 82-91.